Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
|Videos|August 29, 2011
Current and Upcoming Lung Cancer Research
Author(s)Ramaswamy Govindan, MD
Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.
Advertisement
Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.
Advertisement
Related to this article
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
5